References
- Lowe K. C. Perfluorochemicals in vascular medicine. Vase. Med. Rev. 1994; 5: 15–32
- Zuck T. F., Riess J. G. Current status of injectable oxygen carriers. Crit, Rev. Clin. Lab. Sci. 1994; 31: 295–324
- Lowe K. C. Perfluorochemical respiratory gas carriers: applications in medicine and biotechology. Science Prog. 1997; 80: 169–193
- Ingram D. A., Forman M.B., Murray J. J. Phagocytic activation of human neutrophils by the detergent component of Fluosol. Am. J. Pathol. 1992; 140: 1081–1087
- Ingram D. A., Forman M. B., Murray J. J. Activation of complement by Fluosol attributable to the Pluronic detergent micelle structure. J. Cardiovasc. Pharmacol. 1992; 22: 456–461
- Forman M. B., Ingram D. A., Murray J. J. Attenuation of myocardial reperfusion injury by perfluorochemical emulsions. Clin. Hemorheol. 1992; 12: 121–140
- Forman M. B., Pitarys C. J., Vildibill H. D., Lambert T. L., Ingram D. A., Virmani R., Murray J. J. Pharmacologic perturbation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion. J. Am. Coll. Cardiol. 1992; 19: 205–216
- Schaer G. L., Hurscy T. L., Abrahams S. L., Buddcmeier K., Ennis B., Rodriguez R., Hubbell J. P., Moy J., Parrillo J. E. Reduction in reperfusion-induced myocardial injury in dogs by RheothRx Injection (Poloxamer 188 N.F.), a hemorheological agent that alters neutrophil function. Circulation 1994; 90: 2964–2975
- Schaer G. L., Spaccavento L. J., Browne K. F., Krueger K. A., Krichbaum D., Phelan J. M., Fletcher W. O., Grines C. L., Edwards S., Jolly M. K., Gibbons R. J. Beneficial effects of RheothRx Injection in patients receivinf thrombolytic therapy for acute myocardial infarction. Circulation 1996; 94: 298–307
- Riess J. G., Lc Blanc M. Preparation of perfluorochemical emulsions for biomedical use: principles, materials and methods. Blood Substitutes: Preparation, Physiology and Medical Applications, K.C. Lowe. Ellis Horwood, Chichester 1988; 94–129
- Bentlcy P. K., Davis S. S., Johnson O. L., Lowe K. C., Washington C. Purification of Pluronic F-68 for perfluorochemical emulsification. J. Pharm. Pharmac. 1989; 41: 661–663
- Neilson C. P., Crowley J. J., Vestal R. E., Connolly M. J. Impaired beta-adrenoceptor function, increased leukocyte respiratory burst, and bronchial hyperresponsiveness. J. Allergy Clin. Immunol. 1992; 90: 825–832
- Lane T. A., Krukonis V. Reduction in the toxicity of a component of an artificial blood substitute by supercritical fluid fractionation. Transfusion 1988; 28: 375–378
- Edwards CM., Lowe K.C., Trabelsi H., Lucas P., Cambon A. Novel fluorinated surfactants for perfluorochemical cmulsification: biocompatibility assessments of glycosidic and polyol derivatives. Art. Cells, Blood Subs., and Immob. Biotech. 1997; 25: 255–260
- Snedecor G. W., Cochran W. G. Statistical Methods8th Edn. Iowa Stale College Press, Ames 1989
- Cawrse N. W., De Pomerai D. I., Lowe K. C. Effects of Pluronic F-68 on 2-deoxyglucose uptake and amino acid incorporation into chick embryonic fibroblasts in vitro. Biomed. Sci. 1991; 2: 180–182
- King A. T., Davey M. R., Mellor I. R., Mulligan B. J., Lowe K. C. Surfactant effects on yeast cells. Enzyme Microb. Technol. 1991; 13: 148–153
- ICI Surfactant Data Sheet, ‘Synperonic’ PE/F68, TPDS7KB2. 1994
- Smith T. M., Stcinhorn D. M., Thusu K., Fuhrman B. P., Dandona P. A liquid perfluorochemical decreases the in vitro production of reactive oxygen species by alveolar macrophages. Crit. Care Med. 1995; 23: 1533–1539